ERBB2 and biliary tract cancer: Trastuzumab plus chemotherapy, mainly paclitaxel, was efficient in patients with ERBB2-amplified tumors, as previously described in breast, colon, oesogastric adenocarcinoma [1, 6, 7] and biliary tract cancer [24].